Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Apr;2(2):147-157.
doi: 10.2217/hep.15.2. Epub 2015 May 5.

Chemoembolization of hepatocellular carcinoma with HepaSphere™

Katerina Malagari  1   2   1   2 , Anastasia Pomoni  1   1 , Dimitrios Filippiadis  2   2 , Dimitrios Kelekis  1   1
Affiliations
Review

Chemoembolization of hepatocellular carcinoma with HepaSphere™

Katerina Malagari et al. Hepat Oncol. 2015 Apr.

Abstract

This review discusses the current data on Hepasphere™ in the treatment of hepatocellular carcinoma. HepaSphere is a drug-loadable microsphere that can be bound with doxorubicin, epirubicin, cisplatin or oxaliplatin. In vitro and in vivo studies confirm lower systemic exposure to the drug and fewer systemic doxorubicin-related side effects. Studies suggest that this technique is better tolerated than conventional lipiodol-based chemoembolization (c-TACE). In intermediate and early stage hepatocellular carcinoma - nonresponsive to curative treatments - complete response and partial response rates range from 22.2 to 48% and 43.7 to 51%, respectively. Studies with survival as an end-point are needed and head-to-head comparisons with other drug-eluting beads are necessary.

Keywords: conventional chemoembolization; drug-eluting chemoembolization; hepatocellular carcinoma.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure K Malagari has received honoraria from Biosphere Medical for Satellite Lectures in Interventional Radiology Meetings. The authors have no relevant affiliations of financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

References

    1. Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology. 2012;262(1):43–58. - PubMed
    1. de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. J. Hepatol. 2012;56(Suppl 1.):s75–s87. - PubMed

    2. • Landmark prospective randomized trial documenting survival advantage with chemoembolization.

    1. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164–1171. - PubMed

    2. • Landmark prospective randomized trial documenting survival advantage with chemoembolization.

    1. Llovet JM, Real MI, Montana X, et al. Arterial chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet. 2002;359:1734–1739. - PubMed
    1. Mitchell DG, Bruix J, Sherman M, Sirlin CB. LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, consensus of the LI-RADS Management Working Group and future directions. Hepatology. 2014 Epub ahead of print. - PubMed

    2. •Prospective randomized trial comparing drug eluting chemoembolization with conventional chemoembolization.

LinkOut - more resources